How much omega-3 fish oil do labels and trials use?

Capsule strengths and label doses
LabelCapsuleBottleDaily dose
Vascepa (icosapent ethyl)0.5 g or 1 g1240 capsules of 0.5 g, 120 of 1 g14 g: four 0.5 g or two 1 g capsules twice daily, with food1
Lovaza (omega-3-acid ethyl esters)1 g2120 capsules24 g: one 4-gram dose (4 capsules) or two 2-gram doses2

The Vascepa label gives 4 grams a day, as four 0.5 g or two 1 g capsules twice daily with food, and the Lovaza label gives 4 grams a day as one dose or two.12

Capsule strengths and label doses

The table is set at the top of the page

Both labels indicate the capsules as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia of 500 mg/dL or more; the Vascepa label also indicates them, as an adjunct to maximally tolerated statin therapy, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adults with triglycerides of 150 mg/dL or more and established cardiovascular disease, or diabetes mellitus and 2 or more additional risk factors.12 The Vascepa patient information caps the 0.5 g capsules at 8 a day and the 1 g capsules at 4 a day, with food.1 Only these two prescription capsules were found in DailyMed and the trial registry; no maker's leaflet giving supplement strengths was fetched.

What the trials gave

TrialDose and schedulePeopleLength
REDUCE-IT (Bhatt, 2019)Icosapent ethyl 2 g twice daily (4 g a day), or placebo38179 statin-treated patients with cardiovascular disease, or diabetes and other risk factors, and fasting triglycerides of 135 to 499 mg/dL3Median follow-up 4.9 years3
STRENGTH (Nicholls, 2020)4 g/d of omega-3 carboxylic acids, or corn oil413 078 statin-treated patients at high cardiovascular risk with high triglycerides and low HDL cholesterol, 6539 per arm4Median 38.2 months on study drug; stopped early4
VITAL (Manson, 20194)Fish-oil capsule 1 g/day with 840 mg n-3 fatty acids (EPA 460 mg, DHA 380 mg), or placebo, in a 2×2 factorial trial that also tested vitamin D3525,871 men aged ≥50 and women aged ≥555Median 5.3 years (range 3.8-6.1)5
ASCEND (Bowman, 2018)1-g capsules of n-3 fatty acids, or olive-oil placebo, once a day615,480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease6Mean follow-up 7.4 years6

VITAL's authors say its single dose did not permit exploration of dose-response; in their discussion of mechanisms, not as a trial result, they write that the dose-response curve for most effects plateaus at 1 g/day or lower.5 The only stepped regimen the search found is in a placebo-controlled trial on the Lovaza label of 663 people with symptomatic paroxysmal or persistent atrial fibrillation: 8 g/day for 7 days, then 4 g/day for 23 weeks, with recurrent atrial fibrillation or flutter at a higher rate than placebo.2 A search of labels, PubMed and ClinicalTrials.gov found no label or trial on cycles of omega-3 dose.

What regulators say about intake

EFSA concluded that supplemental EPA and DHA up to 5 g a day do not raise safety concerns for adults.7 A 2002 FDA letter on a dietary supplement health claim finds EPA and DHA as dietary supplements safe and lawful under its health-claim rule, provided daily intakes of EPA and DHA from conventional food and dietary supplement sources do not exceed three grams per person per day.8 The two figures differ: EFSA's 5 g a day counts supplemental EPA and DHA, while the FDA letter's three grams counts food and supplements together.78 Both labels say published studies or trials of omega-3 acids showed prolonged bleeding time that did not exceed normal limits or produce clinically significant bleeding episodes, and both say patients also taking anticoagulants or antiplatelet agents are monitored.12

Storage

The Vascepa label gives storage at 20°C to 25°C, with excursions permitted to 15°C to 30°C.1 The Lovaza patient information gives room temperature, 20°C to 25°C, and says not to freeze; its prescribing information gives 25°C, with excursions permitted to 15° to 30°C.2 The two labels give storage for capsules only, and the labels give no stability data for any other form.

Frequently asked questions

How do you take omega-3 capsules?

The Vascepa label gives its capsules with food, and says to swallow them whole.1 The Lovaza label says clinical studies gave it with meals.2

Can omega-3 powder or capsule contents be mixed with water?

The labels and trials searched cover capsules only, with no oral powder and no mixing instruction. The Lovaza label says not to break open, crush, dissolve or chew the capsules.2

How is a dose in mg turned into capsules or mL?

The Lovaza label counts a 4-gram dose as 4 capsules.2 The labels searched give no liquid fish-oil concentration, so nothing here turns a dose into mL.

References

  1. DailyMed (US National Library of Medicine). These highlights do not include all the information needed to use VASCEPA ® safely and effectively. See full prescribing information for VASCEPA. VASCEPA ® (icosapent ethyl) capsules, for oral use Initial U.S. Approval: 2012. 2026. dailymed.nlm.nih.gov
  2. DailyMed (US National Library of Medicine). These highlights do not include all the information needed to use LOVAZA safely and effectively. See full prescribing information for LOVAZA. LOVAZA (omega-3-acid ethyl esters capsules), for oral use Initial U.S. Approval: 2004. 2026. dailymed.nlm.nih.gov
  3. PubMed. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. 2019. pubmed.ncbi.nlm.nih.gov
  4. JAMA via PMC. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. 2020. pmc.ncbi.nlm.nih.gov
  5. NEJM via PMC. Marine Omega-3 Fatty Acids and Prevention of Vascular Disease and Cancer. 2018. pmc.ncbi.nlm.nih.gov
  6. PubMed. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. 2018. pubmed.ncbi.nlm.nih.gov
  7. EFSA. EFSA assesses safety of long-chain omega-3 fatty acids. 2012. efsa.europa.eu
  8. FDA (letter, copy hosted by LSU AgCenter). Letter Regarding Dietary Supplement Health Claim for Omega-3 Fatty Acids and Coronary Heart Disease (Docket No. 91N-0103). 2002. www2.lsuagcenter.com